Sam S. Chang
#145,752
Most Influential Person Now
Sam S. Chang's AcademicInfluence.com Rankings
Sam S. Changphilosophy Degrees
Philosophy
#7837
World Rank
#11103
Historical Rank
Logic
#4872
World Rank
#6204
Historical Rank

Download Badge
Philosophy
Why Is Sam S. Chang Influential?
(Suggest an Edit or Addition)Sam S. Chang's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. (2016) (915)
- Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. (2007) (815)
- Treatment of Non‐Metastatic Muscle‐Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2017) (612)
- Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (474)
- Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial (2018) (399)
- Analysis of early complications after radical cystectomy: results of a collaborative care pathway. (2002) (350)
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (297)
- A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. (2007) (285)
- Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. (2004) (281)
- Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. (2013) (268)
- Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. (2003) (268)
- Overview of prostate-specific membrane antigen. (2004) (243)
- Protocol for the examination of specimens from patients with carcinoma of the prostate gland. (2009) (235)
- Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. (2010) (233)
- Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. (2011) (215)
- Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. (2015) (193)
- Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines (2015) (186)
- Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial. (2014) (186)
- Re: Smoking Cessation: A Report of the Surgeon General. (2020) (182)
- Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. (2003) (181)
- Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. (2007) (181)
- ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. (2013) (173)
- Enhanced Recovery Pathways Versus Standard Care After Cystectomy: A Meta-analysis of the Effect on Perioperative Outcomes. (2016) (172)
- Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. (2005) (165)
- Contemporary open radical cystectomy: analysis of perioperative outcomes. (2008) (161)
- Causes of increased hospital stay after radical cystectomy in a clinical pathway setting. (2002) (152)
- Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. (2010) (142)
- Renal cell carcinoma with renal vein and inferior vena caval involvement: clinicopathological features, surgical techniques and outcomes. (2005) (137)
- Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. (2003) (134)
- Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. (2004) (131)
- Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. (2011) (130)
- Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. (2014) (123)
- Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. (2015) (121)
- Kidney cancer, version 3.2015. (2015) (119)
- Association of procedure volume with radical cystectomy outcomes in a nationwide database. (2007) (119)
- Complications of inguinal and pelvic lymphadenectomy for squamous cell carcinoma of the penis: a contemporary series. (2004) (118)
- Tumour volume is an independent predictor of prostate‐specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer (2006) (114)
- Health related quality of life in patients treated with radical cystectomy and urinary diversion for urothelial carcinoma of the bladder: development and validation of a new disease specific questionnaire. (2003) (113)
- Impact of surgeon and hospital volume on outcomes of radical prostatectomy. (2010) (109)
- Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. (2002) (101)
- National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. (2012) (100)
- Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. (2011) (100)
- Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline Part I. (2021) (99)
- Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. (2002) (97)
- Renal cell cancer histological subtype distribution differs by race and sex (2016) (94)
- Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. (2007) (94)
- Preservation of the anterior vaginal wall during female radical cystectomy with orthotopic urinary diversion: technique and results. (2002) (94)
- Complications of contemporary radical nephrectomy: comparison of open vs. laparoscopic approach. (2004) (94)
- Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? (2013) (94)
- Effects of obesity and height on prostate‐specific antigen (PSA) and percentage of free PSA levels among African‐American and Caucasian men (2006) (91)
- Penile cancer: clinical presentation, diagnosis, and staging. (2010) (91)
- Predicting blood loss and transfusion requirements during radical prostatectomy: the significant negative impact of increasing body mass index. (2004) (90)
- The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. (2013) (89)
- Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology (2015) (88)
- Loss of the Urothelial Differentiation Marker FOXA1 Is Associated with High Grade, Late Stage Bladder Cancer and Increased Tumor Proliferation (2012) (85)
- Recent Changes in Prostate Cancer Screening Practices and Epidemiology (2017) (82)
- Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. (2011) (82)
- Second prize: frequency of benign renal cortical tumors and histologic subtypes based on size in a contemporary series: what to tell our patients. (2007) (76)
- National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. (2012) (75)
- Kidney cancer, version 2.2014. (2014) (73)
- Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. (2004) (72)
- Testicular Cancer, Version 2.2015. (2015) (69)
- Benefit of radical cystectomy in the elderly patient with significant co-morbidities. (2004) (67)
- Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. (2011) (66)
- Volume outcomes of cystectomy--is it the surgeon or the setting? (2012) (65)
- Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. (2012) (64)
- Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. (2008) (64)
- Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy (2014) (62)
- Prostate-specific Membrane Antigen (PSMA)-specific Monoclonal Antibodies in the Treatment of Prostate and Other Cancers (2004) (61)
- Smaller prostate size predicts high grade prostate cancer at final pathology. (2010) (59)
- Voiding function in women with orthotopic neobladder urinary diversion. (2012) (59)
- Increasing use of observation among men at low risk for prostate cancer mortality. (2015) (57)
- Partial nephrectomy safely preserves renal function in patients with a solitary kidney. (2003) (57)
- Increased body mass index predicts increased blood loss during radical cystectomy. (2004) (56)
- Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. (2015) (56)
- Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. (2014) (55)
- Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. (2011) (55)
- Pathological findings of gynecologic organs obtained at female radical cystectomy. (2002) (52)
- Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. (2010) (52)
- ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma (2012) (51)
- Urethral recurrence in patients following orthotopic urinary diversion. (2004) (50)
- The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy (2016) (49)
- Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. (2002) (49)
- Impact of positive apical surgical margins on likelihood of biochemical recurrence after radical prostatectomy. (2009) (48)
- Kidney Cancer (2016) (48)
- Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. (2014) (48)
- Patterns of initial transitional cell recurrence in patients after cystectomy. (2006) (47)
- Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma (2015) (47)
- Urinary diversion trends at a high volume, single American tertiary care center. (2009) (47)
- Comparison of transfusion requirements between open and robotic‐assisted laparoscopic radical prostatectomy (2010) (46)
- Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: implications for cancer detection and biopsy strategy. (2006) (46)
- Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. (2021) (46)
- Single-center comparison of purely laparoscopic, hand-assisted laparoscopic, and open radical nephrectomy in patients at high anesthetic risk. (2003) (46)
- Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial (2019) (45)
- The clinical role of prostate-specific membrane antigen (PSMA). (2002) (45)
- Lymph node yield at radical cystectomy predicts mortality in node-negative and not node-positive patients. (2012) (44)
- Impact of positive surgical margins after radical prostatectomy. (2006) (43)
- Racial variation in the quality of surgical care for bladder cancer (2014) (43)
- Orthotopic neobladder following radical cystectomy in patients with high perioperative risk and co-morbid medical conditions. (2002) (42)
- Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy (2008) (40)
- Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. (2009) (40)
- Sperm banking: use and outcomes in patients treated for testicular cancer (2007) (40)
- Short term complications from transurethral resection of bladder tumor. (2016) (37)
- Management of carcinoma in situ of the bladder: best practice and recent developments (2015) (37)
- Re: Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. (2018) (37)
- Prostate cancer serum biomarker discovery through proteomic analysis of alpha‐2 macroglobulin protein complexes (2008) (37)
- A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. (2016) (37)
- Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. (2015) (36)
- A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. (2008) (35)
- Predictors of Recurrence, Progression-Free and Overall Survival Following Open Versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Follow-Up. (2020) (35)
- Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder (2014) (35)
- Decreasing blood loss in patients treated with radical cystectomy: a prospective randomizes trial using a new stapling device. (2003) (35)
- Safely reducing length of stay after open radical retropubic prostatectomy under the guidance of a clinical care pathway (2005) (35)
- Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. (2009) (34)
- Bladder cancer, version 3.2020 (2020) (34)
- The role of systemic cytotoxic therapy for prostate cancer (2009) (34)
- Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. (2017) (34)
- Radical cystectomy for bladder cancer: the case for early intervention. (2005) (33)
- Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy. (2004) (32)
- The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. (2002) (32)
- Triaging Office-Based UrologY Procedures During the COVID-19 Pandemic (2020) (32)
- Racial variation in the quality of surgical care for prostate cancer. (2012) (31)
- Society of Urologic Oncology position statement: Redefining the management of hormone‐refractory prostate carcinoma (2005) (31)
- Primary endoscopic management versus open revision of ureteroenteric anastomotic strictures after urinary diversion--single institution contemporary series. (2009) (30)
- Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma--does it affect survival? (2008) (30)
- Tumour size, tumour complexity, and surgical approach are associated with nephrectomy type in small renal cortical tumours treated electively (2012) (29)
- Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. (2014) (29)
- An expressed retrogene of the master embryonic stem cell gene POU5F1 is associated with prostate cancer susceptibility. (2014) (29)
- Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues (2000) (27)
- Testicular cancer. (2012) (27)
- Increasing Utilization of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer in the United States (2014) (27)
- ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer (2018) (26)
- Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. (2020) (25)
- Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: Analysis of patient outcomes (2009) (25)
- Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation (2004) (25)
- Treatment options for hormone-refractory prostate cancer. (2007) (25)
- Retroperitoneal versus transperitoneal robotic-assisted laparoscopic partial nephrectomy: a matched-pair, bicenter analysis with cost comparison using time-driven activity-based costing (2017) (24)
- Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist. (2013) (24)
- Non-muscle-invasive bladder cancer: the role of radical cystectomy. (2005) (23)
- Dilemmas in the treatment of urothelial cancers of the prostate. (2009) (23)
- Current controversies in the treatment of high-risk prostate cancer (2008) (23)
- Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. (2011) (23)
- Monoclonal antibodies and prostate-specific membrane antigen. (2004) (23)
- Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. (2014) (22)
- Blood loss associated with radical cystectomy: a prospective, randomized study comparing Impact LigaSure vs. stapling device. (2014) (21)
- Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology (2009) (21)
- Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer (2017) (21)
- Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. (2016) (21)
- The evidence‐based pathway for peri‐operative management of open and robotically assisted laparoscopic radical prostatectomy (2007) (21)
- Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Data Base (2009) (20)
- Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. (2012) (20)
- Locally advanced prostate cancer: the role of surgical management (2009) (20)
- Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. (2016) (20)
- Beneficial impact of a clinical care pathway in patients with testicular cancer undergoing retroperitoneal lymph node dissection. (2002) (19)
- Prognostic factors in T3b renal cell carcinoma (2009) (19)
- Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. (2008) (19)
- Association between Preoperative Albumin Levels and Length of Stay after Radical Cystectomy (2017) (19)
- Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients. (2021) (19)
- Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. (2018) (19)
- Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: A tale of two methods (2010) (19)
- Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: What They Are and How To Manage Them. (2020) (18)
- Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Clinical Data Base: the impact of hospital case volume, hospital size and geographical region on 48 000 patients (2009) (18)
- Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma. (2017) (18)
- Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer (2008) (18)
- Non-muscle invasive bladder cancer. (2013) (17)
- Routine postoperative intensive care monitoring is not necessary after radical cystectomy. (2002) (17)
- Morbidity and efficacy of genitofemoral nerve grafts with radical retropubic prostatectomy. (2005) (17)
- Therapeutic Ultrasound and Prostate Cancer (2017) (16)
- Lack of P16ink4a over expression in penile squamous cell carcinoma is associated with recurrence after lymph node dissection. (2015) (16)
- Comparative analysis of whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. (2010) (16)
- TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. (2017) (16)
- Paracolic recurrence: the importance of wide excision of the spermatic cord at retroperitoneal lymph node dissection. (2002) (16)
- Impact of complications and hospital-free days on health related quality of life 1 year after radical cystectomy. (2014) (15)
- Prostate volume modifies the association between obesity and prostate cancer or high-grade prostatic intraepithelial neoplasia (2007) (14)
- Multiple physician recommendations for prostate cancer treatment: a Pandora's box for patients? (2010) (14)
- Assessing urinary diversion experience in urologic residency programs-are we adequately training the next generation? (2006) (14)
- Eosinophilic cystitis presenting as a recurrent symptomatic bladder mass following intravesical mitomycin C therapy. (2002) (14)
- Positive influence of robotically assisted laparoscopic prostatectomy on the collaborative‐care pathway for open radical prostatectomy (2006) (14)
- Utilizing the Tumor‐Node‐Metastasis Staging for Prostate Cancer: The Sixth Edition, 2002 (2008) (14)
- Assessing retroperitoneal lymphadenectomy experience in United States urological residency programs. (2007) (13)
- Guideline-based management of non-muscle invasive bladder cancer (2015) (13)
- Toxicity following high‐dose salvage radiotherapy after radical prostatectomy (2007) (13)
- Treatment of clinical stage I germ cell tumors. (2002) (13)
- Short- and long-term complications of therapy for testicular cancer. (2007) (12)
- Neovesical‐urethral anastomotic stricture after orthotopic urinary diversion: presentation and management (2007) (12)
- Current chemotherapeutic approaches for androgen-independent prostate cancer. (2006) (11)
- Causes of increased length of stay following radical cystectomy. (2002) (11)
- Margin control in open radical prostatectomy: what are the real outcomes? (2010) (11)
- Conduit Urinary Diversion. (2018) (10)
- Effects of tumor size and location on survival in upper tract urothelial carcinoma after nephroureterectomy (2018) (10)
- Exploring the effects of luteinizing hormone-releasing hormone agonist therapy on bone health: implications in the management of prostate cancer. (2003) (10)
- Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model. (2020) (9)
- Open renal biopsy: comorbidities and complications in a contemporary series (2009) (9)
- A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT. (2019) (9)
- Re: Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. (2015) (9)
- 8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer (2020) (8)
- Re: Prognostic Factors and Risk Groups in T1G3 Non-Muscle-Invasive Bladder Cancer Patients Initially Treated with bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. (2016) (8)
- Improvements in Safety and Recovery Following Cystectomy: Reassessing the Role of Pre-Operative Bowel Preparation and Interventions to Speed Return of Post-Operative Bowel Function (2013) (8)
- Inflammatory myofibroblastic tumor of the urinary bladder in a 27‐year‐old woman with systemic lupus erythematosus (2008) (7)
- Role and Indications of Organ-Sparing "Radical" Cystectomy: The Importance of Careful Patient Selection and Counseling. (2018) (7)
- Optimizing outcomes for octogenarians with invasive bladder cancer: One size does not fit all. (2013) (7)
- Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma (2016) (7)
- 300: Prospective Assessment of Health Related Quality of Life (HRQOL) Urinary Diversion Following Radical Cystectomy and Urinary Diverision: Comparison of Orthotopic Neobladder Versus Ileal Conduit Patients (2004) (7)
- High-Risk Non-Muscle Invasive Bladder Cancer: Selecting the Appropriate Patient for Timely Cystectomy. (2020) (7)
- A phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin–unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT (2019) (6)
- Re: Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer. (2018) (6)
- Feasibility study for image guided kidney surgery: assessment of required intraoperative surface for accurate image to physical space registrations (2006) (6)
- An Empiric Evaluation of the Effect of Variation in Intensity of Followup for Surgically Treated Renal Neoplasms on Cancer Specific Survival (2017) (6)
- Management of High-grade T1 Urothelial Carcinoma (2018) (6)
- Robotic assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: Comparison of short-term biochemical recurrencefree survival (2010) (5)
- Lymphoma presenting as a solitary renal hilar mass. (2002) (5)
- Re: Long-Term Outcome of Patients with Frequently Recurrent Non-Muscle-Invasive Bladder Carcinoma Treated with One Perioperative plus Four Weekly Instillations of Mitomycin C followed by Monthly bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomise (2017) (5)
- 1870 ALVIMOPAN, A PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONIST, ACCELERATES GASTROINTESTINAL RECOVERY AND DECREASES LENGTH OF HOSPITAL STAY AFTER RADICAL CYSTECTOMY (2013) (5)
- Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma Who Have Progressed following Treatment with Platinum-Based Chemotherapy: A Single-Arm, Multicentre, Phase 2 Trial. (2016) (5)
- Treating octogenarians with muscle-invasive bladder cancer: preoperative opportunities for increasing the benefits of surgical intervention. (2014) (5)
- Re: Improving Selection Criteria for Early Cystectomy in High-Grade T1 Bladder Cancer: A Meta-Analysis of 15,215 Patients. (2015) (5)
- Cost considerations in the management of bladder cancer (2017) (5)
- ANTIBODIES TO THE INTERNAL AND EXTERNAL DOMAINS OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) REACT WITH TUMOR-ASSOCIATED NEOVASCULATURE (1999) (5)
- Primary renal carcinoid tumor managed with laparoscopic partial nephrectomy. (2006) (5)
- The impact of hospital volume on short-term and long-term outcomes for patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma. (2020) (4)
- RADICAL NEPHRECTOMY SURGICAL OUTCOMES IN THE UNIVERSITY HEALTHSYSTEM CONSORTIUM DATABASE: THE IMPACT OF HOSPITAL CASE VOLUME, HOSPITAL SIZE AND GEOGRAPHIC LOCATION ON 40,000 PATIENTS (2008) (4)
- 12th Annual meeting of the Society of Urologic Oncology (SUO) bladder cancer sessions I and II summary report. (2012) (4)
- Positive efficacy and safety phase 3 results in both CIS and papillary cohorts BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) after IL-15RαFc superagonist N-803 (Anktiva) and BCG infusion. (2022) (4)
- 1605: Early and Delayed Return of Urinary Continence after Radical Prostatectomy: Results of a Prospective Comparative Trial of an Open Retropubic vs. Robotic Approach (2007) (4)
- The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer (2014) (4)
- Re: EAU Guidelines on Penile Cancer: 2014 Update. (2016) (4)
- Performance-enhancing supplement use in patients with testicular cancer. (2005) (4)
- Polycystic kidney disease (1989) (4)
- Kidney cancer: The prognostic value of urinary collecting system invasion (2009) (4)
- THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA: MP86‐17 (2017) (4)
- MP13-03 IMPACT OF SYNCHRONOUS BLADDER CANCER ON RECURRENCE-FREE SURVIVAL AFTER SURGICAL TREATMENT FOR PRIMARY URETHRAL CANCER: RESULTS FROM THE INTERNATIONAL COLLABORATION ON PRIMARY URETHRAL CARCINOMA (ICPUC) (2014) (4)
- 726: Squamous Cell Carcinoma of the Penis: A Contemporary Review of Lymph Node Disease (2005) (3)
- Re: Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study. (2018) (3)
- Re: Risks and Benefits of Adjuvant Radiotherapy after Inguinal Lymphadenectomy in Node-Positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel. (2019) (3)
- 456: Sperm Banking: Use and Outcomes in Patients Treated for Testicular Cancer (2006) (3)
- Short- and long-term issues regarding urethral management in male radical-cystectomy patients (2005) (3)
- Re: Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. (2019) (3)
- Re: Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. (2020) (3)
- Re: Gender-Specific Differences in Clinicopathologic Outcomes following Radical Cystectomy: An International Multi-Institutional Study of More than 8000 Patients. (2016) (3)
- IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (2022) (3)
- Re: Intravesical rAd-IFNα/Syn3 for Patients with High-Grade, bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. (2018) (3)
- A phase I/II multi-center study of intravesical nanoparticle albumin-bound rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer. (2015) (3)
- Urological SurveyUrological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of OncologyRe: Conditional Survival after Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time (2015) (3)
- A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT. (2020) (3)
- Re: Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. (2018) (3)
- 1818 PERIOPERATIVE BLOOD TRANSFUSION INCREASES THE RISK OF OVERALL MORTALITY IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2010) (3)
- The influence of provider characteristics and market forces on response to financial incentives. (2017) (3)
- Management of high risk metastatic prostate cancer: defining risk at the time of initial treatment failure. (2006) (3)
- Principles of Bladder Cancer Surgery (2014) (3)
- MP32-20 RECOVERY OF ERECTILE FUNCTION AFTER RADICAL PROSTATECTOMY: IDENTIFICATION OF TRAJECTORY CLUSTER GROUPS (2014) (3)
- Catching Those Who Fall Through the Cracks: Integrating a Follow-Up Process for Emergency Department Patients with Incidental Radiologic Findings. (2022) (3)
- A phase I/II study of albumin-bound rapamycin nanoparticles in the treatment of bacillus calmette-guerin refractory non-muscle invasive transitional cell bladder cancer. (2016) (3)
- Re: Immediate versus Deferred Chemotherapy after Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-Label, Randomised Phase 3 Trial. (2016) (2)
- PD09-05 PHASE 2/3 CLINICAL RESULTS OF IL-15RΑFC SUPERAGONIST N-803 WITH BCG IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) CARCINOMA IN-SITU (CIS) PATIENTS. (2021) (2)
- Re: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy after Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit f (2017) (2)
- Biology of PSMA As a Diagnostic and Therapeutic Target (2004) (2)
- Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer. (2015) (2)
- Re: Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-Muscle-Invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 Patients (2017) (2)
- 698: Laparoscopic, Hand Assisted Laparoscopic and open Simple Nephrectomy for Technically Challenging Cases (2007) (2)
- Re: New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. (2017) (2)
- Accuracy of the Extent of Bladder Cancer Nodal Metastases Found at Pelvic Lymphadenectomy at the Time of Cystectomy: Relation to Primary Tumor Stage (2010) (2)
- Re: HER2 as a Target in Invasive Urothelial Carcinoma. (2016) (2)
- 1586 BLOOD LOSS ASSOCIATED WITH RADICAL CYSTECTOMY A PROSPECTIVE RANDOMIZED STUDY COMPARING IMPACT LIGASURE VERSUS STAPLING DEVICE (2012) (2)
- Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma (2021) (2)
- Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy. (2019) (2)
- Re: MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. (2015) (2)
- Management of Bladder Cancer (2015) (2)
- Re: Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. (2020) (2)
- The prevention of extraction site incisional hernia after robotic-assisted radical prostatectomy (2021) (2)
- Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion. (2018) (2)
- EFFECT OF PRE-OPERATIVE NUTRITIONAL DEFICIENCY ON MORTALITY AFTER RADICAL CYSTECTOMY FOR BLADDER CANCER (2011) (2)
- Re: Conditional Survival after Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. (2015) (2)
- 943 PROGNOSTIC FACTORS AND OUTCOMES AFTER DEFINITIVE TREATMENT FOR PRIMARY URETHRAL CANCER: RESULTS FROM THE INTERNATIONAL COLLABORATION ON PRIMARY URETHRAL CARCINOMA (2013) (2)
- Re: Impact of Suboptimal Neoadjuvant Chemotherapy on Peri-Operative Outcomes and Survival after Robot-Assisted Radical Cystectomy: A Multicentre Multinational Study. (2018) (2)
- Complications of Transrectal Ultrasound-Guided Prostate Biopsy (2013) (2)
- The urinary tract (2012) (2)
- The Role and Importance of Timely Radical Cystectomy for High-Risk Non-muscle-Invasive Bladder Cancer. (2018) (2)
- Fifth Joint Meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association (2010) (2)
- Re: A Floating Hydrogel System Capable of Generating CO2 Bubbles to Diminish Urinary Obstruction after Intravesical Instillation. (2016) (2)
- Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. (2017) (2)
- Re: EMT- and Stroma-Related Gene Expression and Resistance to PD-1 Blockade in Urothelial Cancer. (2019) (2)
- Re: Mutational Patterns in Chemotherapy Resistant Muscle-Invasive Bladder Cancer. (2019) (2)
- Re: Long-Term Follow-up of TaG1 Non-Muscle-Invasive Bladder Cancer. (2017) (2)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (2)
- Re: Next-Generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. (2019) (2)
- Re: Bacillus Calmette-Guérin (BCG) Therapy Lowers the Incidence of Alzheimer's Disease in Bladder Cancer Patients. (2020) (2)
- PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION POST-NEOADJUVANT ANDROGEN DEPRIVATION THERAPY: COMPARISON OF 7311 AND HYBRITECH PM2J004.5 IN PARAFFIN EMBEDDED PROSTATE TISSUE (1999) (1)
- IDENTIFICATION OF DISTINCT OUTCOMES CLUSTERS FOR URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY (2009) (1)
- Re: Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model. (2019) (1)
- Re: DaPeCa-1: Diagnostic Accuracy of Sentinel Lymph Node Biopsy in 222 Patients with Penile Cancer at Four Tertiary Referral Centres-A National Study from Denmark. (2017) (1)
- ANALYSIS OF EARLY AND LATE HOSPITAL READMISSIONS FOLLOWING RADICAL CYSTECTOMY (2009) (1)
- Predictors of recurrence in patients with high-risk pathology after prostatectomy (2015) (1)
- PD11-10 A 10-ITEM CHECKLIST CHECKLIST IMPROVES REPORTING OF CRITICAL PROCEDURAL ELEMENTS DURING TRANSURETHRAL RESECTION OF BLADDER TUMOR (2016) (1)
- Re: Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors. (2015) (1)
- Re: Utility and Significance of Ureteric Frozen Section Analysis during Radical Cystectomy. (2017) (1)
- Re: Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery after Surgery Protocol. (2018) (1)
- Re: Propensity Score Analysis of Radical Cystectomy versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. (2017) (1)
- Laparoscopic radical nephrectomy: When minimally invasive surgery may be too invasive (2003) (1)
- Re: Treatment for Metastatic Penile Cancer after First-Line Chemotherapy Failure: Analysis of Response and Survival Outcomes. (2016) (1)
- Re: Effectiveness of Adjuvant Chemotherapy after Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-Invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis. (2019) (1)
- The adverse consequences of delaying radical cystectomy (2006) (1)
- Re: Discrepancies in Staging, Treatment, and Delays to Treatment May Explain Disparities in Bladder Cancer Outcomes: An Update from the National Cancer Data Base (2004-2013). (2019) (1)
- Re: Contemporary Use Trends and Survival Outcomes in Patients Undergoing Radical Cystectomy or Bladder-Preservation Therapy for Muscle-Invasive Bladder Cancer. (2018) (1)
- Re: Intravesical rAd-IFNα/Syn3 for Patients with High-Grade, bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study (2018) (1)
- Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer (2022) (1)
- Re: A Systematic Review and Meta-Analysis of Clinicopathologic Factors Linked to Intravesical Recurrence after Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. (2016) (1)
- Re: National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. (2019) (1)
- Chapter 19 – Prognosis and Management of Invasive Transitional Cell Carcinoma (2005) (1)
- Re: PET/Computed Tomography in Renal, Bladder, and Testicular Cancer. (2017) (1)
- Re: The Effect of Intravesical Chemotherapy in the Prevention of Intravesical Recurrence after Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Meta-Analysis. (2016) (1)
- Re: Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma after Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial. (2019) (1)
- Re: Health-Related Quality of Life after Radical Cystectomy and Neobladder Reconstruction in Women: Impact of Voiding and Continence Status (2015) (1)
- Re: Safety and Efficacy of Temsirolimus as Second Line Treatment for Patients with Recurrent Bladder Cancer. (2019) (1)
- Re: Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer (2018) (1)
- Re: Human Papillomavirus (HPV) Genotype- and Age-Specific Analyses of External Genital Lesions among Men in the HPV Infection in Men (HIM) Study. (2015) (1)
- Re: Impact of Adjuvant Chemotherapy in Patients with Adverse Features and Variant Histology at Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder: Does Histologic Subtype Matter? (2020) (1)
- Treating asymptomatic patients with hormone‐refractory prostate cancer: hormonal manipulations for the urologist (2008) (1)
- 1465: Incidence and Significance of Hgpin on Prostate Biopsy: Results of a Large, Community-Based Pathology Referral Center (2005) (1)
- Re: Disseminated Mycobacterium bovis Infection Post-Kidney Transplant following Remote Intravesical BCG Therapy for Bladder Cancer. (2019) (1)
- NCCN Kidney Cancer Clinical Practice Guidelines in Oncology (2011) (1)
- Advancing prostate cancer: treatment options for the urologist. (2006) (1)
- 527 CHANGING UTILIZATION OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPIES FOR MUSCLE-INVASIVE UROTHELIAL CARCINOMA AFTER PUBLICATION OF LANDMARK MANUSCRIPTS (2012) (1)
- Detection of Extravesical Disease: A Lack of Bladder Cancer Markers (2009) (1)
- MP18-15 EFFICACY OF HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) AS A PRIMARY MONOTHERAPY FOR LOW RISK LOCALIZED PROSTATE CANCER: OUTCOMES FROM THE ENLIGHT TRIAL (2011) (1)
- 178: Examining Contemporary Urinary Diversion: A Review of Changing Practice Patterns Diversion Selectivity (2007) (1)
- Re: Association between Treatment of Superficial Bladder Cancer and 10-Year Mortality in Older Adults with Multiple Chronic Conditions. (2020) (1)
- Association between PSA and leptin, adiponectin, HbA1c, or C-peptide among African-American and Caucasian men (2007) (1)
- Re: Endoscopic Molecular Imaging of Human Bladder Cancer Using a CD47 Antibody. (2013) (1)
- Implementation of a comprehensive prehabilitation program for patients undergoing radical cystectomy. (2022) (1)
- Re: Oncologic Outcomes following Robot-Assisted Radical Cystectomy with Minimum 5-Year Follow-up: The Roswell Park Cancer Institute Experience. (2016) (1)
- Pharmacological treatments for BCG-refractory cancer of the urinary bladder (2008) (1)
- 1122: Assessing Intraoperative Factors that Prevent Orthotopic Urinary Diversion in Patients Undergoing Radical Cystectomy (2005) (1)
- Re: Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival. (2016) (1)
- Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. (2018) (1)
- Re: The Association of ABO Blood Type with Disease Recurrence and Mortality among Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. (2016) (1)
- Lap pak for abdominal retraction. (2012) (1)
- Re: Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model. (2015) (1)
- Re: Association of Germline Variants in the APOBEC3 Region with Cancer Risk and Enrichment with APOBEC-Signature Mutations in Tumors. (2018) (1)
- Predicting the Probability of 90-day Survival in Elderly Bladder Cancer Patients Treated with Radical Cystectomy (2019) (1)
- Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer (2016) (1)
- IMMEDIATE SURGICAL OUTCOMES FOR RADICAL PROSTATECTOMY IN THE UNIVERSITY HEALTHSYSTEM CONSORTIUM DATABASE: THE IMPACT OF HOSPITAL CASE VOLUME, HOSPITAL SIZE, AND GEOGRAPHIC REGION ON 48,000 PATIENTS (2008) (1)
- Re: SUCCINCT: An Open-Label, Single-Arm, Non-Randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-Line Treatment for Patients with Advanced Urothelial Carcinoma. (2015) (1)
- Re: Predictive Factors for Residual Cancer in Second Transurethral Resection for Non-Muscle-Invasive Bladder Cancer. (2020) (1)
- Re: Benefits of Adjuvant Chemotherapy for Bladder Cancer. (2017) (1)
- WAITING TIME FROM DIAGNOSIS TO NEPHRECTOMY FOR RENAL CELL CARCINOMA: DOES IT AFFECT SURVIVAL? (2008) (1)
- 939 USE OF ROBOTIC ASSISTED RADICAL CYSTECTOMY VERSUS OPEN RADICAL CYSTECTOMY FOR BLADDER CANCER IS ASSOCIATED WITH DECREASED BLOOD LOSS AND PERIOPERATIVE TRANSFUSION RATE (2011) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- SURVIVAL OUTCOMES IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY AS A COMPONENT OF MULTI-MODAL THERAPY FOR RENAL CELL CARCINOMA (2008) (0)
- Re: Treatment Trends and Outcomes for Patients with Lymph Node-Positive Cancer of the Penis. (2020) (0)
- Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer. (2020) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- Re: Concurrent Chemotherapy is Associated with Improved Survival in Elderly Patients with Bladder Cancer Undergoing Radiotherapy (2018) (0)
- Re: Association between Number of Endoscopic Resections and Utilization of bacillus Calmette-Guérin Therapy for Patients with High-Grade, Non-Muscle-Invasive Bladder Cancer. (2018) (0)
- Re: Prognostic Risk Stratification Derived from Individual Patient Level Data for Men with Advanced Penile Squamous Cell Carcinoma Receiving First-Line Systemic Therapy. (2016) (0)
- Re: Multicenter Evaluation of the Role of UroVysion FISH Assay in Surveillance of Patients with Bladder Cancer: Does FISH Positivity Anticipate Recurrence? (2017) (0)
- MP31-15 IMPACT OF HEALTH LITERACY ON DISCHARGE DISPOSITION FOLLOWING RADICAL CYSTECTOMY (2016) (0)
- Re: Clinical and Therapeutic Factors Associated with Adverse Pathological Outcomes in Clinically Node-Negative Patients Treated with Neoadjuvant Cisplatin-Based Chemotherapy and Radical Cystectomy. (2017) (0)
- Re: Efficacy of Long-Acting Octreotide on Reducing Mucus Production in Patients with Ileal Neobladder (2018) (0)
- Re: Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. (2017) (0)
- Re: Sequential Intravesical Mitomycin plus Bacillus Calmette-Guérin for Non-Muscle-Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial. (2016) (0)
- MP84-19 EXTENT OF LYMPH NODE DISSECTION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA IS ASSOCIATED WITH BETTER SURVIVAL (2015) (0)
- Re: Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C versus bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-Risk Non-Muscle-Invasive Bladder Cancer. (2018) (0)
- Re: Randomized Trial of Narrow-Band versus White-Light Cystoscopy for Restaging (Second-Look) Transurethral Resection of Bladder Tumors. (2015) (0)
- Re: Multiparametric 3-T MRI for Differentiating Low- versus High-Grade and Category T1 versus T2 Bladder Urothelial Carcinoma. (2016) (0)
- Re: Spillover Effects of the Hospital Readmissions Reduction Program on Radical Cystectomy Readmissions. (2020) (0)
- Editorial Comment. (2020) (0)
- Re: Intravesical Gemcitabine in Combination with Mitomycin C as Salvage Treatment in Recurrent Non-Muscle-Invasive Bladder Cancer (2017) (0)
- MP82-13 IMPACT OF VARIANT HISTOLOGY ON SURVIVAL AND RESPONSE TO CHEMOTHERAPY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA (2020) (0)
- Re: Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis from the National Cancer Data Base. (2018) (0)
- 305: A Prospective Randomized Trial of Early vs. Traditional Post-Operative Feeding After Radical Cystectomy and Urinary Diversion (2004) (0)
- 1816 EFFECTS OF PRE-OPERATIVE NUTRITIONAL DEFICIENCY ON 90-DAY MORTALITY AND OVERALL SURVIVAL IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR BLADDER CANCER (2010) (0)
- Re: Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-A Prospective Double-Blind Clinical Study. (2019) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- Re: The Impact of Re-Transurethral Resection on Clinical Outcomes in a Large Multicentre Cohort of Patients with T1 High-Grade/Grade 3 Bladder Cancer Treated with bacille Calmette-Guérin. (2018) (0)
- Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: . (2019) (0)
- Re: The Prognostic Significance of the Early Postoperative Neutrophil-to-Lymphocyte Ratio in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy. (2017) (0)
- The 6th American Urological Association and the Japanese Urological Association International Affiliate Society Meeting (2011) (0)
- 1648: The Influence of Histopathologic Method on Prostatic Carcinoma Incidence and Gleason Grade in Cystoprostatectomy Specimens (2007) (0)
- 1444 ACCESS TO CARE INFLUENCES ADHERENCE TO GUIDELINES FOR MANAGEMENT OF MUSCLE-INVASIVE BLADDER CANCER (2013) (0)
- Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology. (2023) (0)
- Re: Response Rate to Chemotherapy after Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. (2019) (0)
- Re: Extended versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder in Patients Undergoing Radical Cystectomy. (2020) (0)
- Abstract A113: Association between NSAIDs and PSA, prostate volume, and prostate cancer (2008) (0)
- Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology. (2023) (0)
- PD52-08 PRE-OPERATIVE NARCOTIC USE IS ASSOCIATED WITH INCREASING LENGTH OF STAY AND POST-OPERATIVE COMPLICATIONS IN PATIENTS UNDERGOING RADICAL CYSTECTOMY (2019) (0)
- Optical attenuation as an effective biomarker for the early detection of bladder cancer (2022) (0)
- Re: Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link. (2015) (0)
- Urothelial carcinoma of the bladder and upper tracts (2007) (0)
- Re: Gene Expression Test for the Non-Invasive Diagnosis of Bladder Cancer: A Prospective, Blinded, International and Multicenter Validation Study. (2016) (0)
- Re: Population-Based Assessment of Racial/Ethnic Differences in Utilization of Radical Cystectomy for Patients Diagnosed with Bladder Cancer. (2019) (0)
- 696: Positive Influence of Robotic Assisted Laparoscopic Prostatectomy on the Collaborative Care Pathway for Open Radical Prostatectomy (2005) (0)
- Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma (2017) (0)
- Re: Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer. (2015) (0)
- Re: Frequent PD-L1 Expression in Primary and Metastatic Penile Squamous Cell Carcinoma: Potential Opportunities for Immunotherapeutic Approaches. (2018) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- Re: Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. (2018) (0)
- Re: Racial and Economic Disparities in the Treatment of Penile Squamous Cell Carcinoma: Results from the National Cancer Database. (2016) (0)
- Re: Cost Considerations for Systemic Therapy for Patients with Advanced Genitourinary Malignancies. (2020) (0)
- Re: Intraoperative Continuous Norepinephrine Infusion Combined with Restrictive Deferred Hydration Significantly Reduces the Need for Blood Transfusion in Patients Undergoing Open Radical Cystectomy: Results of a Prospective Randomised Trial. (2016) (0)
- Re: Intermediate-Term Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Urothelial Carcinoma. (2015) (0)
- Non-muscle Invasive Bladder Cancer: Identifying Patients to Consider Timely, Initial Cystectomy (2020) (0)
- Re: The Health Effects of Electronic Cigarettes. (2017) (0)
- 73 RACIAL VARIATION IN THE UTILIZATION OF HIGH-VOLUME SURGEONS AND HOSPITALS FOR RADICAL PROSTATECTOMY (2011) (0)
- Re: Predicting Local Failure after Radical Cystectomy in Patients with Bladder Cancer: Implications for the Selection of Candidates at Adjuvant Radiation Therapy. (2019) (0)
- Commentary on significance of positive surgical margins. (2008) (0)
- 1908 AN UPDATED MODEL AND NOMOGRAM FOR SURVIVAL FOLLOWING CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (2013) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- Re: Intracorporeal Robot-Assisted Radical Cystectomy, together with an Enhanced Recovery Programme, Improves Postoperative Outcomes by Aggregating Marginal Gains. (2019) (0)
- 1493: Significance of ASAP and HGPIN on Prostate Biopsy: Implications for Cancer Detection and Biopsy Strategy (2005) (0)
- Re: Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy. (2016) (0)
- Re: Increasing Age is Not Associated with Toxicity Leading to Discontinuation of Treatment in Patients with Urothelial Non-Muscle-Invasive Bladder Cancer Randomised to Receive 3 Years of Maintenance bacille Calmette-Guérin: Results from European Organisation for Research and Treatment of Cancer Geni (2018) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
- 1750 NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER: TRENDS IN UTILIZATION AND IMPLICATIONS FOR PATHOLOGIC STAGING IN THE NATIONAL CANCER DATABASE (2013) (0)
- Re: Neutrophil-to-Lymphocyte Ratio as a Bladder Cancer Biomarker: Assessing Prognostic and Predictive Value in SWOG 8710 (2017) (0)
- 1619 ACCESS TO CARE PREDICTS ADEQUATE PELVIC LYMPH NODE DISSECTION IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER (2013) (0)
- PD6-05 CHANGE IN PREDICTED PROGNOSIS AFTER RADICAL PROSTATECTOMY DURING FOLLOW-UP IN AN ACTIVE SURVEILLANCE COHORT (2015) (0)
- Re: Contemporary Cost-Effectiveness Analysis Comparing Sequential bacillus Calmette-Guerin and Electromotive Mitomycin versus bacillus Calmette-Guerin Alone for Patients with High-Risk Non-Muscle-Invasive Bladder Cancer. (2015) (0)
- 1320: Patterns of Initial Transitional Cell Carcinoma Recurrence in Patients after Cystectomy (2005) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- Re: Sustained-Release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. (2019) (0)
- 452: Obesity is Positively Correlated with PSA Recurrence and Time to PSA Recurrence in Patients Undergoing Radical Prostatectomy (2004) (0)
- Re: Lessons from 151 Ureteral Reimplantations for Postcystectomy Ureteroenteric Strictures: . (2019) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles Of Oncology. (2020) (0)
- 1251: Partial Nephrectomy: Alive and well in an Era of Minimally Invasive Surgery (2007) (0)
- 1497: Predictive Value of Proliferative Inflammatory Atrophy (PIA) for Prostate Cancer on Repeat Prostate Biopsy (2006) (0)
- MP10-03 THE INFLUENCE OF ACCESS TO CARE ON ADHERENCE TO CLINICAL PRACTICE GUIDELINES FOR TESTIS CANCER (2014) (0)
- Re: Impact of Molecular Subtypes in Muscle-Invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy (2018) (0)
- Re: Cigarette Smoking is Associated with Adverse Pathological Response and Increased Disease Recurrence amongst Patients with Muscle-Invasive Bladder Cancer Treated with Cisplatin-Based Neoadjuvant Chemotherapy and Radical Cystectomy: A Single-Centre Experience. (2020) (0)
- Re: Adjuvant Cisplatin-Based Combined Chemotherapy for Lymph Node (LN)-Positive Urothelial Carcinoma of the Bladder (UCB) after Radical Cystectomy (RC): A Retrospective International Study of >1500 Patients. (2016) (0)
- 1185 RECOVERY OF URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY: IDENTIFICATION OF TRAJECTORY CLUSTER GROUPS (2012) (0)
- Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors. (2016) (0)
- Re: Metastases in Normal-Sized Pelvic Lymph Nodes: Detection with Diffusion-Weighted MR Imaging. (2015) (0)
- MP25-11 PHYSICIAN-LEVEL VARIATION IN THE USE OF OBSERVATION FOR LOCALIZED PROSTATE CANCER (2016) (0)
- Re: Assessment of Quality of Life, Information, and Supportive Care Needs in Patients with Muscle and Non-Muscle Invasive Bladder Cancer across the Illness Trajectory. (2020) (0)
- Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model (2022) (0)
- Re: Racial Disparity and Survival Outcomes between African-American and Caucasian American Men with Penile Cancer. (2019) (0)
- Renal surgery and its impact on chronic kidney disease: a continuing evolution in decision making. (2014) (0)
- Re: Contemporary Treatment Patterns and Outcomes of Sarcomatoid Bladder Cancer. (2019) (0)
- Re: The Cancer of the Bladder Risk Assessment (COBRA) Score: Estimating Mortality after Radical Cystectomy. (2018) (0)
- PD41-04 ORAL NUTRITION INTERVENTION IN PATIENTS UNDERGOING RADICAL CYSTECTOMY: A PROSPECTIVE, RANDOMIZED CONTROLLED TRIAL (2018) (0)
- 1426 CONTEMPORARY MANAGEMENT OF SMALL RENAL MASSES: PARTIAL NEPHRECTOMY IS ASSOCIATED EXCLUSIVELY WITH TUMOR ANATOMIC COMPLEXITY (2012) (0)
- Association between surgical volume and survival among patients with variant histologies of bladder cancer. (2021) (0)
- Abstract 5067: An expressed retrogene of master embryonic stem cell factor OCT4 alters prostate cancer susceptibility (2014) (0)
- Re: The Challenges of Bacillus of Calmette-Guerin (BCG) Therapy for High Risk Non Muscle Invasive Bladder Cancer Treatment in Older Patients. (2020) (0)
- RELATIONSHIP BETWEEN PROSTATE VOLUME AND PATHOLOGIC GRADE OF PROSTATE CANCER (2009) (0)
- MP20-06 HOW A TRAINING PROGRAM INFLUENCES EARLY CAREER DECISION-MAKING AND JOB RETENTION IN UROLOGY (2021) (0)
- PD18-03 THE IMPACT OF HOSPITAL VOLUME ON SHORT-TERM AND LONG-TERM OUTCOMES FOR PATIENTS UNDERGOING RADICAL NEPHROURETERECTOMY WITH UPPER TRACT UROTHELIAL CARCINOMA (2020) (0)
- 441 RACIAL VARIATION IN THE QUALITY OF CARE AMONG PATIENTS UNDERGOING CYSTECTOMY FOR BLADDER CANCER (2011) (0)
- Re: Human Epidermal Growth Factor Receptor 2 Expression is More Important than bacillus Calmette Guerin Treatment in Predicting the Outcome of T1G3 Bladder Cancer. (2019) (0)
- RELATIONSHIP OF URINARY FUNCTION FOLLOWING RADICAL PROSTATECTOMY WITH MEDICAL COMORBIDITIES AND GLOBAL QUALITY OF LIFE PARAMETERS (2009) (0)
- Re: Occult Metastases in Pelvic Lymphadenectomy Specimens from Patients with Urothelial Carcinoma of the Bladder. (2017) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
- Assessing health related quality of life following radical cystectomy and urinary diversion Development and validation of thevanderbilt cystectomy index (2003) (0)
- Re: Long-Term Survival Outcomes with Intravesical Nanoparticle Albumin-Bound Paclitaxel for Recurrent Non-Muscle-Invasive Bladder Cancer after Previous bacillus Calmette-Guérin Therapy. (2019) (0)
- 966 ONCOLOGIC OUTCOMES FOLLOWING ROBOTIC-ASSISTED LAPAROSCOPIC VS. OPEN RADICAL PROSTATECTOMY FOR INTERMEDIATE AND HIGH-RISK PROSTATE CANCER (2013) (0)
- 324: The Outcomes in Patients with Pathologic Carcinoma-in-Situ-Only Disease at Radical Cystectomy (2004) (0)
- LOWER SERUM ALBUMIN LEVELS ARE ASSOCIATED WITH LONGER LENGTHS OF STAY (LOS) FOLLOWING CYSTECTOMY: THE NATIONAL SURGICAL QUALITY IMPROVEMENT PROGRAM: MP96‐17 (2017) (0)
- Re: Advanced Small Cell Carcinoma of the Bladder: Clinical Characteristics, Treatment Patterns and Outcomes in 960 Patients and Comparison with Urothelial Carcinoma. (2017) (0)
- Re: Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: One-Year Results of a Multicentre Prospective Cohort Study. (2016) (0)
- Re: Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. (2015) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles Of Oncology. (2021) (0)
- Re: Adjuvant Sandwich Chemotherapy plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy: A Randomized Phase 2 Trial. (2019) (0)
- Re: Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. (2020) (0)
- Re: The Effect of Broader, Directed Antimicrobial Prophylaxis Including Fungal Coverage on Perioperative Infectious Complications after Radical Cystectomy. (2017) (0)
- Re: Prediction Model for Recurrence Probabilities after Intravesical Chemotherapy in Patients with Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, Including External Validation. (2017) (0)
- MP58-08 DO LOW RISK MEN IN AN ACTIVE SURVEILLANCE COHORT REQUIRE ANNUAL BIOPSIES? (2014) (0)
- Bladder, Penis and Urethral Cancer, and Basic Principles Of Oncology. (2021) (0)
- Re: PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases. (2020) (0)
- Re: Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. (2017) (0)
- Re: Predictors of Nodal Upstaging in Clinical Node Negative Patients with Penile Carcinoma: A National Cancer Database Analysis (2018) (0)
- Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-Label, Ra (2019) (0)
- Re: Extended versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. (2019) (0)
- Re: Intravesical bacillus Calmette-Guérin with Interferon-Alpha versus Intravesical bacillus Calmette-Guérin for Treating Non-Muscle-Invasive Bladder Cancer (2017) (0)
- Testicle Carcinoma Surveillance Counterpoint: USA (2013) (0)
- 8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer (2020) (0)
- PD02-03 UNDERLYING REASONS ASSOCIATED WITH HOSPITAL READMISSION FOLLOWING UROLOGIC SURGERY IN THE U.S. (2016) (0)
- Re: Care Quality and Variability in the Use of Intravesical Therapy for Initial Treatment of Nonmuscle Invasive Bladder Cancer within a Large, Diverse Integrated Delivery System. (2020) (0)
- Re: Urine Cytology is a Feasible Tool for Assessing Erythematous Bladder Lesions after Bacille Calmette-Guérin (BCG) Treatment. (2020) (0)
- Urologic Oncology: Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology. (2023) (0)
- PD55-06 COMPARISON OF MRI/FUSION VERSUS TRUS CONFIRMATORY BIOPSY IN ACTIVE SURVEILLANCE PATIENTS (2019) (0)
- 574: Prospective Assessment of Health Related Quality of Life (HRQOL) at One Year Following Radical Cystectomy and Urinary Diversion (2007) (0)
- Re: Outcome of Patients with Micropapillary Urothelial Carcinoma following Radical Cystectomy: ERBB2 (HER2) Amplification Identifies Patients with Poor Outcome (2015) (0)
- Re: Clinical Significance of Preoperative C-Reactive Protein and Squamous Cell Carcinoma Antigen Levels in Patients with Penile Squamous Cell Carcinoma. (2018) (0)
- IMPACT OF POSITIVE APICAL SURGICAL MARGINS (SM) ON THE LIKELIHOOD OF BIOCHEMICAL RECURRENCE (BCR) AFTER PROSTATECTOMY (2009) (0)
- COMPARISON OF 3-YEAR CANCER CONTROL OUTCOMES IN ROBOTIC-ASSISTED LAPAROSCOPIC PROSTATECTOMY (RALP) VERSUS RADICAL RETROPUBIC PROSTATECTOMY (RRP) FOR PROSTATE CANCER (2009) (0)
- Prostate Cancer: Clinical Case Scenarios. (2018) (0)
- 1413 PREDICTING THE PROBABILITY OF 90-DAY SURVIVAL IN ELDERLY BLADDER CANCER PATIENTS TREATED WITH RADICAL CYSTECTOMY (2011) (0)
- 1900 WORTH A SECOND LOOK: RATES OF UPSTAGING AT THE TIME OF RADICAL CYSTECTOMY AFTER RESTAGING TURBT FOR PERSISTENT T1 UROTHELIAL CARCINOMA (2012) (0)
- Re: Impact of Perioperative Chemotherapy on Survival in Patients with Advanced Primary Urethral Cancer: Results of the International Collaboration on Primary Urethral Carcinoma. (2015) (0)
- Re: Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. (2020) (0)
- 977 ABO BLOOD TYPE IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA (2012) (0)
- Re: Partial Bladder Boost Using Lipiodol Marking during Image-Guided Radiotherapy for Bladder Cancer. (2019) (0)
- Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline. (2023) (0)
- Re: Comparing Open Radical Cystectomy and Robot-Assisted Laparoscopic Radical Cystectomy: A Randomized Clinical Trial. (2015) (0)
- Solifenacin at 3 Years: A Review of Efficacy and Safety (2008) (0)
- Re: Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer. (2019) (0)
- UTILIZATION OF SYSTEMIC THERAPY IN PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY AS A COMPONENT OF MULTI-MODAL THERAPY FOR RENAL CELL CARCINOMA (2008) (0)
- Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model. (2023) (0)
- Re: Trends in the Use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-Invasive Bladder Cancer: A Sign of Changing Tides. (2016) (0)
- Re: Prognostic Significance of Lymphatic, Vascular and Perineural Invasion for Bladder Cancer Patients Treated by Radical Cystectomy. (2019) (0)
- 7of Extravesical Disease: A Lack of Bladder Cancer Markers (2010) (0)
- Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter (2022) (0)
- Re: Pathologic Response in Patients Receiving Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Is Therapeutic Effect Owing to Chemotherapy or TURBT? (2019) (0)
- Re: Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. (2019) (0)
- Re: Fluorescence-Guided Bladder Tumour Resection: Impact on Survival after Radical Cystectomy. (2015) (0)
- MP13-08 GENDER INFLUENCE ON PRESENTATION, MANAGEMENT, AND OVERALL SURVIVAL IN PRIMARY URETHRAL CANCER (2014) (0)
- Re: Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. (2017) (0)
- 1226 PERIOPERATIVE COST COMPARISON OF ROBOTIC AND OPEN RADICAL CYSTECTOMY FOR BLADDER CANCER (2012) (0)
- Re: Evidenced-Based Clinical Practice Guideline for Upper Tract Urothelial Carcinoma (summary-Japanese Urological Association, 2014 edition). (2015) (0)
- 1763 TREATMENT PATTERNS AND SURVIVAL OUTCOMES OF PATIENTS 50 YEARS OLD AND YOUNGER UNDERGOING DEFINITIVE TREATMENT FOR BLADDER UROTHELIAL CELL CARCINOMA (2012) (0)
- 1646 STATIN USE IS ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS UNDERGOING SURGERY FOR RENAL CELL CARCINOMA (2013) (0)
- Re: Cost-Effectiveness of Neoadjuvant Chemotherapy before Radical Cystectomy for Muscle-Invasive Bladder Cancer. (2016) (0)
- MP44-02 POST-OPERATIVE NARCOTIC PRESCRIBING PATTERNS FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY (2019) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
- Re: National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging. (2020) (0)
- Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG. (2022) (0)
- Kidney: renal cell carcinoma (2007) (0)
- How a Large Academic Training Program Influences Early Career Decision-making and Employment Stability in Urology. (2022) (0)
- Re: Potential Impact of 18F-FDG PET/CT on Patients Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. (2015) (0)
- Re: SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor. (2017) (0)
- Treatment principles for nonmuscle invasive bladder cancer (2008) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- Re: Usefulness of pT1 Substaging in Papillary Urothelial Bladder Carcinoma. (2016) (0)
- Re: Factors Influencing the Length of Stay after Radical Cystectomy: Implications for Cancer Care and Perioperative Management. (2016) (0)
- Differentiation of Bladder Cancer from Inflammation with Polarization-Sensitive Optical Coherence Tomography (2022) (0)
- Bladder, Penis, and Urethral Cancer, and Basic Principles of Oncology. (2023) (0)
- Impact of PSMA-targeted PET/CT in the clinical management of men with advanced prostate cancer. (2022) (0)
- 1030 ASSESSMENT OF THE 2002 AJCC NODAL STAGING OF BLADDER UROTHELIAL CARCINOMA (2010) (0)
- Re: Nuclear CD24 Drives Tumor Growth and is Predictive of Poor Patient Prognosis (2018) (0)
- PD12-06 INCREASED PAYMENT FOR OFFICE-BASED MANAGEMENT OF BLADDER CANCER: UNINTENDED CONSEQUENCES IN A FEE-FOR-SERVICE ENVIRONMENT (2015) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
- Re: Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. (2016) (0)
- Re: Characterization of Late Recurrence after Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. (2019) (0)
- Re: Occupation and Bladder Cancer Phenotype: Identification of Workplace Patterns That Increase the Risk of Advanced Disease beyond Overall Incidence. (2019) (0)
- Re: Comprehensive Genomic Profiling of 295 Cases of Clinically Advanced Urothelial Carcinoma of the Urinary Bladder Reveals a High Frequency of Clinically Relevant Genomic Alterations. (2017) (0)
- 488: Assessing Urinary Diversion Experience in Urologic Residency Training: Is it Adequate? (2005) (0)
- 528 PRE-OPERATIVE NUTRITIONAL STATUS IS AN IMPORTANT PREDICTOR OF SURVIVAL FOLLOWING SURGERY FOR RENAL CELL CARCINOMA (2011) (0)
- PRIMARY ENDOSCOPIC MANAGEMENT VERSUS OPEN REVISION OF URETEROENTERIC ANASTOMOTIC STRICTURES FOLLOWING URINARY DIVERSION-SINGLE INSTITUTION CONTEMPORARY SERIES (2009) (0)
- Re: Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: . (2018) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
- Re: Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-Muscle Invasive Bladder Cancer Patients. (2017) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- Bladder, Penis and Urethral Cancer, and Basic Principles Of Oncology. (2020) (0)
- New Approaches in the Treatment of Advanced Prostate Cancer (2006) (0)
- Re: Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. (2019) (0)
- 847: Is Length of Positive Surgical Margin an Independent Predictor of Biochemical Progression After Prostatectomy? Results of a Multivariate Analysis (2004) (0)
- Re: Orthotopic Neobladder vs. Ileal Conduit Urinary Diversion: A Long-Term Quality-of-Life Comparison. (2017) (0)
- Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. (2020) (0)
- 1878 SMALL CELL CARCINOMA OF THE BLADDER: CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS (2013) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles OF Oncology. (2021) (0)
- Re: The Impact of Non-Urothelial Variant Histology on Oncological Outcomes following Radical Cystectomy. (2020) (0)
- MP31-16 THE IMPACT OF HEALTH LITERACY ON SURGICAL OUTCOMES FOLLOWING RADICAL CYSTECTOMY (2016) (0)
- Racial variation in the quality of care among patients undergoing cystectomy for bladder cancer (2011) (0)
- Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15RαFc superagonist N-803 plus BCG. (2023) (0)
- MP42-10 TREATMENT AND ASSOCIATED SURVIVAL TRENDS FOR LOCALIZED SMALL CELL CARCINOMA OF THE BLADDER (2022) (0)
- Re: Cost-Effectiveness of Pembrolizumab in Second-Line Advanced Bladder Cancer. (2019) (0)
- Laparoscopy and Robotics Biochemical Recurrenceefree Survival After Robotic-assisted Laparoscopic vs Open Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer (2014) (0)
- Urological Oncology: Bladder, Penis and Urethra Cancer, and Basic Principles of Oncology. (2021) (0)
- QIM22-205: Implementation of a Comprehensive Pre-Habilitation Program for Patients Undergoing Radical Cystectomy (2022) (0)
- A COMPARISON OF AMERICAN JOINT COMMITTEE ON CANCER PATHOLOGIC STAGE T3a VERSUS T3b UROTHELIAL CANCER: ANALYSIS OF PATIENT OUTCOMES (2008) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2021) (0)
- Treatment of muscle-invasive bladder cancer (2010) (0)
- MP60-03 IMPACT OF POST-OPERATIVE COMPLICATIONS AND THE NUMBER OF ‘HOSPITAL-FREE DAYS’ FOLLOWING RADICAL CYSTECTOMY ON QUALITY OF LIFE AT ONE YEAR (2014) (0)
- MP49-01 FOXA1 LOSS IS ASSOCIATED WITH POOR PROGNOSIS AND SEX-DEPENDENT PHENOTYPES FOLLOWING GENETIC INACTIVATION (2015) (0)
- Re: Incidence of Bladder Cancer after Radiation for Prostate Cancer as a Function of Time and Radiation Modality (2018) (0)
- 1631 DISPARITIES IN THE UTILIZATION OF RADICAL CYSTECTOMY IN YOUNG PATIENTS WITHOUT COMORBIDITY: AN UNFORTUNATE TALE OF MISSED OPPORTUNITY (2013) (0)
- Re: Variation in Performance of Candidate Surgical Quality Measures for Muscle-Invasive Bladder Cancer by Hospital Type. (2016) (0)
- 1803 A PROGNOSTIC MODEL FOR SURVIVAL FOLLOWING CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (2012) (0)
- Office‐Based Cystoscopy: Continued Advances (2012) (0)
- Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer. (2019) (0)
- Re: Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to bacillus Calmette-Guérin. (2017) (0)
- Re: Significance of ERBB2 Overexpression in Therapeutic Resistance and Cancer-Specific Survival in Muscle-Invasive Bladder Cancer Patients Treated with Chemoradiation-Based Selective Bladder-Sparing Approach. (2015) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2020) (0)
- 1656 NATIONAL ASSESSMENT OF NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) PRACTICE PATTERNS: IMMEDIATE POST-OPERATIVE INSTILLATION OF CHEMOTHERAPY (IPOIC) (2011) (0)
- Re: Detrusor Muscle in TUR-Derived Bladder Tumor Specimens: Can we Actually Improve the Surgical Quality? (2017) (0)
- Re: Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. (2017) (0)
- Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement. (2018) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- IMMUNOHISTOCHEMICAL COMPARISON OF FIVE ANTIBODIES TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) IN BENIGN TISSUES (1999) (0)
- Re: Development and External Validation of a Prognostic Tool for Prediction of Cancer-Specific Mortality after Complete Loco-Regional Pathological Staging for Squamous Cell Carcinoma of the Penis. (2016) (0)
- MP5-07 AN EMPIRICAL EVALUATION OF VARIATION IN INTENSITY OF SURVIVORSHIP CARE AND ITS EFFECT ON KIDNEY CANCER-SPECIFIC SURVIVAL (2015) (0)
- Re: Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-Muscle-Invasive Bladder Cancer. (2020) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- Re: STAG2 is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer. (2020) (0)
- Re: Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. (2015) (0)
- 1757 USE OF PELVIC LYMPHADENECTOMY IN RADICAL CYSTECTOMY FOR BLADDER CANCER: 10-YEAR EXPERIENCE AT A SINGLE INSTITUTION (2012) (0)
- MP12-16 SURVEILLANCE IMAGING AFTER T1 RCC: AN OVER-UTILIZATION OR NECESSARY CARE? (2014) (0)
- Follow-up imaging in the first two years after nephrectomy for T1 RCC: Over-use or necessary care? (2016) (0)
- Re: A Multifactorial Model of T Cell Expansion and Durable Clinical Benefit in Response to a PD-L1 Inhibitor. (2019) (0)
- Re: Practical Tips for Safe and Efficient Robotic Cystectomy. (2016) (0)
- Re: Adjuvant Pelvic Radiation is Associated with Improved Survival and Decreased Disease Recurrence in Pelvic Node-Positive Penile Cancer after Lymph Node Dissection: . (2019) (0)
- Urological Oncology: Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology. (2022) (0)
- 629 Impact of salvage surgery and radiotherapy on overall survival in patients with recurrent primary urethral cancer (2016) (0)
- OP3-11 INGUINAL LYMPHADENECTOMY IN PENILE CANCER: RESULTS FROM THE NATIONAL CANCER DATABASE (2014) (0)
- PD31-09 INSTITUTIONAL MODIFICATION OF ANTIBIOTIC PROPHYLAXIS PROTOCOL REDUCES INFECTIOUS COMPLICATIONS FOLLOWING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY (2014) (0)
- Re: Anti-Inflammatory Use May Not Negatively Impact Oncologic Outcomes following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer. (2017) (0)
- Office-based Cystoscopy (2018) (0)
- 1121: Assessing Gender Differences in Pathologic Characteristics and Disease-Specific Outcomes in Radical Cystectomy (2005) (0)
- Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated with Neoadjuvant Chemotherapy. (2020) (0)
- Biodynamic prediction of neoadjuvant chemotherapy response: Results from a prospective multicenter study of predictive accuracy among muscle-invasive bladder cancer patients. (2022) (0)
- Re: Investigation of Multisequence Magnetic Resonance Imaging for Detection of Recurrent Tumor after Transurethral Resection for Bladder Cancer. (2016) (0)
- 848: Tumor Volume is Positively Correlated with Pathologic Stage and PSA Recurrence in Patients Undergoing Radical Prostatectomy (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sam S. Chang?
Sam S. Chang is affiliated with the following schools: